Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, Clinical Neurophysiology, 1(126), p. 68-81

DOI: 10.1016/j.clinph.2014.03.036

Links

Tools

Export citation

Search in Google Scholar

Antiretroviral therapy effects on sources of cortical rhythms in HIV subjects: Responders vs. Mild Responders

This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Objective: We tested the hypothesis that 5. months of combined anti-retroviral therapy (cART) affect cortical sources of resting state cortical electroencephalographic (EEG) rhythms in naïve HIV subjects. Methods: Eyes-closed resting state EEG data were recorded at baseline (i.e. pre-treatment; T0), T1 (after 4. weeks of cART), T2 (after 8. weeks of cART), and T5 (after 5. months of cART) in 38 naïve HIV subjects. EEG data were also recorded in 40 age-matched cognitively normal subjects for control purposes. EEG rhythms of interest were delta (2-4. Hz), theta (4-8. Hz), alpha 1 (8-10.5. Hz), alpha 2 (10.5-13. Hz), beta 1 (13-20. Hz), and beta 2 (20-30. Hz). Cortical EEG sources were estimated by LORETA software. Results: Compared to the control group, the HIV group at T0 showed greater delta sources and lower widespread alpha sources. cART induced a global improvement of biological (viral load, CD4 count) and EEG (delta, alpha) markers, remarkable even after 4. weeks. Compared to HIV Responders (>100. cells/μl at 5-month follow up), the HIV Mild Responders (<100. cells/μl) showed greater parietal delta sources at baseline and lower occipital alpha sources at 5-month follow up. Conclusions: In naïve HIV subjects, 5. months of successful cART affect brain synchronization mechanisms at the basis of the generation of delta and alpha rhythms. Significance: The present EEG markers may be useful secondary neurophysiological end points for pharmacological clinical trials in naïve HIV subjects.